Culling Wildlife for the Sake of Research

A case in which the University of Florida killed birds to protect crop research raises questions on the ethics of field studies’ potential side effects.

Aug 27, 2018
Anna Azvolinsky

ABOVE: Mother and infant sandhill crane in Florida

A news article in the Gainesville Sun last week revealed that researchers at the University of Florida had shot more than 150 wild birds that were eating and damaging crops grown on test plots over the course of 10 years. The culled animals included 105 ring-billed gulls and 47 sandhill cranes, a bird whose population has declined such that the state designated it a threatened species.

In 2016, after reviewing the records of the bird culling, the new director of the University of Florida’s Plant Science Research and Education Unit, Jim Boyer, changed the policy so that only nonlethal means could be used against the cranes. Instead of guns, his group brandished scarecrows and reflective tape.

Environmental groups praised the move. “We at Audubon don’t have a lot of sympathy for folks that are eager to take lethal action against wildlife when that wildlife is seen as an inconvenience,” says Julie Wraithmell, executive director of the Florida Audubon Society. “The important thing is that IFIS [the Institute of Food and Agricultural Sciences] did the right thing. They revisited their policy and changed it.”

The situation brings up a tricky aspect of conducting such field studies—the possible destruction of habitat or wildlife to make room for and protect experiments. How much, if any, is acceptable?

For Clare Palmer, a professor of environmental and animal ethics at Texas A&M University, this answer lies at the intersection of numerous kinds of values, and “each is likely to be weighed differently depending on the individual, although most people will likely think they all matter to some degree,” she writes in an email to The Scientist. These include the individual animal’s value, the importance of the species and its habitat, and the benefit of the study to human welfare. 

“The first line of response in a case like this should surely be to minimize the degree to which these values are actually in conflict,” writes Palmer. “If the birds can be almost wholly kept away from the research crops by repelling them or using barriers, this sounds like the best approach, since then a value conflict doesn’t arise.”

See “Overcoming the Challenges of Studying Endangered Animals”

These issues are not necessarily foremost in scientists’ minds. Afterall, researchers seldom receive extensive training in professional ethics and hardly ever in philosophical ethics, writes Michael Paul Nelson, a professor of environmental ethics and philosophy at Oregon State University, in an email to The Scientist. “And there is pressure on researchers to complete projects and have them be successful. There are powerful interests at play here, as researchers are rewarded by their institutions in ways that sometimes contrast with deep ethical reflection and consideration.”

There are no hard-and-fast rules about handling wildlife threats to field experiments, according to bioethicists. Universities have resources to help, namely, the Institutional Animal Care and Use Committee (IACUC) and the Institutional Review Board review process. Yet, these committees may be operating by standards that don’t place a high value on wildlife. “It’s not obvious that simply because a proposal passes IACUC that it is ethically justified,” writes Nelson. 

Researchers do have to abide by the law. In the case of the birds at the University of Florida, the researchers had obtained a federal permit to kill the birds but, importantly, did not have a state permit to take them out, says Wraithmell. “That was a problem because the Florida sandhill crane is considered a threatened species, and they likely would not have been able to obtain one,” she tells The Scientist

Jennifer Jacquet, an assistant professor of environmental studies at New York University, says there has been a shift in public attitudes about wildlife, and the scientific community should take note. “There is more heightened awareness about the morality around animals’ lives and their treatment,” she says. “It’s important that these conversations about animal welfare are happening with a greater frequency.” 

In a letter this week to the Gainesville Sun, Jack Payne, the senior vice president for agriculture and natural resources at the University of Florida, noted that the policy change from killing the birds to shooing them away was not the result of any complaints but rather the university becoming aware of the situation and holding themselves “to a higher standard.” 

July 2019

On Target

Researchers strive to make individualized medicine a reality


Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.